← Back to Search

Monoclonal Antibodies

Imsidolimab for Hidradenitis Suppurativa

Phase 2
Waitlist Available
Research Sponsored by AnaptysBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in baseline in abscess and inflammatory nodule (an) count at week 16
Awards & highlights

Study Summary

This trial found that imsidolimab was safe and effective in treating hidradenitis suppurativa.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in baseline in abscess and inflammatory nodule (an) count at week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in baseline in abscess and inflammatory nodule (an) count at week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the efficacy of imsidolimab in subjects with HS

Side effects data

From 2021 Phase 2 trial • 8 Patients • NCT03619902
25%
Oropharyngeal pain
13%
Nosocomial infection
13%
Anaemia
13%
Psoriasis
13%
Skin haemorrhage
13%
Lymphadenopathy
13%
Blood glucose increased
13%
C-reactive protein increased
13%
White blood cell count increased
13%
COVID-19
13%
Blood folate decreased
13%
Mitral valve prolapse
13%
Myxomatous mitral valve degeneration
13%
Peripheral swelling
13%
Swelling face
13%
Humerus fracture
13%
Hypokalemia
13%
Presyncope
13%
Acute kidney injury
13%
Vaginal haemorrhage
13%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Imsidolimab

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: ANB019 Biological Humanized Monoclonal Antibody Low DoseExperimental Treatment1 Intervention
Group II: ANB019 Biological Humanized Monoclonal Antibody High DoseExperimental Treatment1 Intervention
Group III: Placebo SolutionPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imsidolimab
2019
Completed Phase 2
~340

Find a Location

Who is running the clinical trial?

AnaptysBio, Inc.Lead Sponsor
16 Previous Clinical Trials
1,499 Total Patients Enrolled
Bruce Randazzo, MDStudy DirectorAnaptysBio, Inc.
10 Previous Clinical Trials
670 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Tennessee
How old are they?
18 - 65
What site did they apply to?
Site 10-110
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
2021. "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04856930.
~40 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top